Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (5.998.994 €): Konservative Eisenchelatals als krankheitsmodifizierende Strategie bei der Parkinson-Krankheit: eine multizentrische, parallele, Placebo-kontrollierte, randomisierte … Hor 01.05.2015 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Text
Konservative Eisenchelatals als krankheitsmodifizierende Strategie bei der Parkinson-Krankheit: eine multizentrische, parallele, Placebo-kontrollierte, randomisierte klinische Studie
Parkinson’s disease (PD) is a major, chronic, non-communicable disease and the 2nd most frequent neurodegenerative disorder worldwide. Excess iron is primarily detected in the substantia nigra pars compacta, where dopaminergic neurons are exposed to high levels of oxidative stress produced by mitochondrial disorders and dopamine metabolism. Our previous preclinical, translational and pilot clinical studies demonstrated that novel iron chelation therapy with the prototypic drug deferiprone (DFP) (i) induces neuroprotection in cell models of PD via a powerful antioxidant effect, (ii) reduces regional siderosis of the brain, (iii) reduces motor handicap via inhibition of catechol-o-methyl transferase, and (iv) slows the progression of motor handicap in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model and in early PD patients. This project now seeks to demonstrate that conservative iron chelation therapy with moderate-dose DFP (30 mg/kg/day) slows the progression of handicap in de novo PD patients while not affecting systemic parameters. The 9-month, parallel-group, randomized, placebo-controlled, multicentre trial will be followed by a 1-month wash-out period. The primary efficacy criterion will be the change in motor and non-motor handicap scores on the Total Movement Disorders Society Unified Parkinson’s Disease Rating Scale to identify disease-modifying and symptomatic effects. The secondary efficacy criterion will be the change in score between baseline and 40 weeks (i.e. probing the disease-modifying effect only). Potential surrogate radiological and biological biomarkers, health economics and societal impacts will be assessed. 17 national, European and international research and innovation activities will be linked with the project. The study results should prompt academic and industrial research on iron chelation as a disease-modifying treatment in neurodegenerative diseases.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| APO-Pharma Inc. Corp | 0,00 € |
| Centre Hospitalier Regional et Universitaire de Lille | 2.604.800 € |
| Chiesi Farmaceutici S.p.A. | 0,00 € |
| Christian-Albrechts-Universitaet ZU Kiel | 0,00 € |
| Eberhard Karls Universitaet Tuebingen | 48.078 € |
| Ecrin European Clinical Research Infrastructure Network | 331.848 € |
| Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i Sunyer | 196.773 € |
| Hospital Clinic de Barcelona | 0,00 € |
| Inserm Transfert SA | 389.491 € |
| Institut National de la Sante et de la Recherche Medicale | 642.888 € |
| Instituto de Medicina Molecular Joao Lobo Antunes | 187.083 € |
| Medizinische Universitat Innsbruck | 226.735 € |
| Philipps Universitaet Marburg | 74.875 € |
| Sorbonne Universite | 82.550 € |
| Stichting Radboud Universitair Medisch Centrum | 256.250 € |
| Stichting Radboud Universiteit | 0,00 € |
| Universitaet ULM | 90.000 € |
| Universitatsklinikum Schleswig-Holstein | 31.181 € |
| University of Newcastle Upon Tyne | 313.370 € |
| Univerzita Karlova | 145.000 € |
Quelle: https://cordis.europa.eu/project/id/633190
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
